Jennifer Boggs

KAI's PKC Program Nabs $340M Deal With Sankyo

Jan. 9, 2006

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today)

Innovive Adding Dual Inhibitor To Oncology Pipeline For CML

Jan. 6, 2006

By Jennifer Boggs

Diversa Cuts Staff, Focuses Efforts On Late-Stage Work

Jan. 6, 2006

By Jennifer Boggs

Diversa Cuts Staff, Focuses Efforts On Late-Stage Work

Jan. 6, 2006

By Jennifer Boggs

Innovive Adding Dual Inhibitor To Oncology Pipeline For CML

Jan. 6, 2006

By Jennifer Boggs

Alcon Signs Kalypsys For Small-Molecule Research

Jan. 5, 2006

By Jennifer Boggs

Alcon Signs Kalypsys For Small-Molecule Research

Jan. 5, 2006

By Jennifer Boggs

Trubion Starts New Year With Potential $840M Wyeth Deal

Jan. 4, 2006

By Jennifer Boggs

Trubion Pharmaceuticals Inc. signed its largest deal to date and set a high bar for 2006 by partnering with Wyeth Pharmaceuticals in a potential $840 million agreement to develop Trubion's small modular immunopharmaceutical (SMIP) platform. (BioWorld Today)